XE9 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xencor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.40 |
| 52 Week High | US$25.20 |
| 52 Week Low | US$6.25 |
| Beta | 0.99 |
| 1 Month Change | -28.09% |
| 3 Month Change | -56.46% |
| 1 Year Change | -70.37% |
| 3 Year Change | -68.93% |
| 5 Year Change | -76.12% |
| Change since IPO | 5.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| XE9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.6% | -1.4% | -0.9% |
| 1Y | -70.4% | -12.5% | 14.1% |
Return vs Industry: XE9 underperformed the German Biotechs industry which returned -12.5% over the past year.
Return vs Market: XE9 underperformed the German Market which returned 14.1% over the past year.
Price Volatility
| XE9 volatility | |
|---|---|
| XE9 Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 5.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: XE9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XE9's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 250 | Bassil Dahiyat | www.xencor.com |
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn’s disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma.
Xencor, Inc. Fundamentals Summary
| XE9 fundamental statistics | |
|---|---|
| Market cap | €474.27m |
| Earnings (TTM) | -€182.75m |
| Revenue (TTM) | €112.00m |
Is XE9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XE9 income statement (TTM) | |
|---|---|
| Revenue | US$127.23m |
| Cost of Revenue | US$229.39m |
| Gross Profit | -US$102.16m |
| Other Expenses | US$105.43m |
| Earnings | -US$207.60m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.92 |
| Gross Margin | -80.30% |
| Net Profit Margin | -163.17% |
| Debt/Equity Ratio | 24.1% |
How did XE9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 10:19 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xencor, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Zhiqiang Shu | Berenberg |
| Alec Stranahan | BofA Global Research |